/ cancer trial
/ Market Analysis
GRAIL Stock Tumbles Despite EPS Beat After Cancer Trial Miss
GRAIL stock plunged nearly 50% in premarket trading after its NHS-Galleri cancer trial missed its primary endpoint.
February 20, 2026